Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Data from patients who continued past one year in the BeyoND study
Objective: To report long-term safety and tolerability data from the ongoing BeyoND study (NCT02726386) for patients who continued treatment past the one-year primary endpoint. Background:…Collective expert perspectives on the use of safinamide as adjunctive therapy for Parkinson’s disease in Japan: Online-based Delphi approach
Objective: To summarize opinions on the optimal patient profile and methods of using safinamide in common clinical scenarios, Japanese movement disorder specialists with expertise in…Basal forebrain contribution to cognitive deficits during medication “off” state in Parkinson’s disease
Objective: We sought to determine whether structural integrity of cholinergic Basal Forebrain (BF) was associated with subjective cognitive deficits experienced during medication “off” time Parkinson’s…CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)
Objective: Safety results from a phase 3, double-blind study of CVT-301 in patients with PD were combined with results from a 4-week, phase 2b, double-blind,…Amantadine DR/ER-Related Reduction in OFF and Dyskinesia Improved Patient-Rated Interference with Activities and Social Interactions
Objective: Evaluate dyskinesia and OFF interference with activities and experiences for persons with Parkinson disease (PWPD), and mitigation with treatment Background: OFF and Dyskinesia remain…IMPACT OF STANDARD-OF-CARE MEDICATIONS ON TIME-OFF READOUTS IN CLINICAL TRIALS. A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH
Objective: To mitigate clinical variability of Time-Off with various therapeutic combinations Background: There is increasing interest to use wearable-based digital health measures to continuously monitor…CVT-301 (levodopa inhalation powder) improves Patient Global Impression of Change (PGIC) over 1 year in patients with Parkinson’s disease (PD): a meta-analysis
Objective: A meta-analysis of PGIC results was performed using combined data from 3 different studies of CVT-301 in patients with PD over a total of…Amantadine DR/ER Efficacy as Early Add-On for Motor Complications in Parkinson’s Disease
Objective: Utilize clinical trial data to analyze amantadine delayed release/extended release (AMT DR/ER) capsules as an early add-on for OFF and dyskinesia in people with…Assessment of Fluctuating Parkinson’s Disease with Sensor-Based Home Monitoring-Feasibility Results
Objective: To implement home-based monitoring (HBM) using wearable devices, a smartphone dedicated app and patient reported outcomes in order to provide a more comprehensive picture…Registry Analysis (In Progress) to Evaluate Clinical Outcomes and Disease Burden of Advanced PD in Patients With Motor Fluctuations and Dyskinesia Managed With Oral Dopaminergic Therapies Versus Device-Aided Therapies
Objective: To compare clinical outcomes of patients with Parkinson's disease (PD) with moderate and severe motor fluctuations or dyskinesia managed with oral dopaminergic medications vs…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 26
- Next Page »